Rheumatoid Arthritis
Conditions
Keywords
rheumatoid arthritis, RA, Mizoribine, DAS28, European League Against Rheumatism
Brief summary
The purpose of this study is to access the efficacy and safety of Mizoribine 150mg qid and 50mg tid in active rheumatoid arthritis patients unsuccessfully treated with disease-modifying antirheumatic drug.
Detailed description
1. EULAR Response after 24weeks of treatment 2. EULAR Response after 12weeks of treatment 3. DAS28 value change 4. KHAQ-20 value change
Interventions
DRUGBredinin tablet 150mg
Bredinin 150mg qd vs Bredinin 50mg tid
DRUGBredinin tablet 50mg
Bredinin 150mg qd vs Bredinin 50mg tid
Sponsors
Chong Kun Dang Pharmaceutical
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Male or female aged from 20 to 80 years old * Signed and dated informed consent document indicating that the patient * Patients must have a diagnosis of Rheumatoid Arthritis(RA) of at least 3months duration as defined by the 2010 American College of Rheumatology(ACR) Classification criteria. * Patients should have a Disease Activity Score 28 greater than or equal to 3.2 (DAS28 ≥ 3.2) and have received treatment with more than 1 kind of disease-modifying antirheumatic drug(including MTX). * ESR≥28mm/h or CRP≥1.0mg/dl at screening.
Exclusion criteria
* At screening, patients have laboratory result as defined by : white blood cell ≤ 3,000/mm3 , Hemoglobin \< 8.5 g/dL, Platelet count \< 100,000/mm3, Serum creatinine \> 2.0 mg/dL, Aspartic Acid Transaminase/Alanine Transaminase ≥ 2\*upper limit of normal , Uric acid ≥ 1.5\*upper limit of normal * Patient must not have bleeding disorder or taking anticoagulant. (But, lt is allowed to take 100mg/day of Asprin) * Patients with a history of operation on index knee joint which could have influence on the result and need to have surgery as determined by investigator. * Patients have severe infection, including moderate respiratory disease and have received treatment with systemic antibiotics within 2 weeks. * Patients have cardiovascular disease or associated disease which is not controlled. * Patients have a history of malignancy within 5years. (But, basal cell or squamous cell carcinoma or carcinoma in situ of the uterine cervix have been treated is allowed) * Patients have hypersensitivity reaction on this drug. * Patients on any other clinical trial or experimental treatment in the past 3months. * Female patients who are breast feeding, pregnant or plan to become pregnant during the trial or for two months following study termination. * Not allowable medication recorded below ; Intra-articular injections within weeks at baseline visit, Patients taking oral steroid over 10mg /day or using new treatment or changing dosage within 4weeks at baseline visit, Using new nonsteroidal antiinflammatory drug within 4 weeks or changing nonsteroidal antiinflammatory drug dosage within 2 weeks at baseline visit. * Having experience of use biologic agent, immunosuppressant, cytostatic preparations within 8weeks at baseline visit. (But, Rituximab is not allowed within 6months) * Start to treatment new disease-modifying antirheumatic drug or need to change dosage of disease-modifying antirheumatic drug which is taking on the trial. (Leflunomide(ARAVA®) is not allowed within 12weeks, But, Cholestyramine is allowed after 48 hours later stopping. if it use three times a day, 8g, for 11days)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| all cause mortality | two years |
Countries
South Korea
Contacts
Primary ContactSung Su Kim, M.D., Ph.D
Outcome results
None listed